Background: In the general population, adiposity exhibits a J-or U-shaped relationship with mortality; however, in catabolic states this relationship is often inversely linear. We have recently documented an age-independent increase in overweight/ obesity in the Pittsburgh Epidemiology of Diabetes Complications Study (EDC) of type 1 diabetes (T1D). As intensified insulin therapy (IIT) may promote weight gain, the impact of weight gain in T1D is of importance. We therefore assessed the association of adiposity with mortality in 655 EDC participants during 20 years of follow-up. Methods: Individuals were categorized as underweight (body mass index (BMI)o20), normal (20p BMI o25), overweight (25p BMI o30), or obese (BMI X30). Cox models were constructed using BMI and covariates at baseline, updated means during follow-up, time variation (reflecting most recent status), and change during adulthood as predictors of mortality. Results: The prevalence of IIT (3 þ insulin shots daily and/or pump) increased from 7 to 82%. Overweight increased by 47% and obesity increased sevenfold. There were 146 deaths. In unadjusted models, BMI (modeled continuously) showed a quadratic relationship with mortality (P ¼ 0.002, o0.0001 o0.0001 for baseline, updated mean and time-varying models, respectively). However, only in the time-varying model were the obese significantly different from the normal weight, whereas the baseline model showed no differences by BMI category. In both the updated mean and time-varying models, the underweight were at greater risk than were the normal weight (Po0.0001 both models). The nonlinear relationship of adiposity with mortality remained after adjustment for diabetes complications and for biological or socioeconomic/lifestyle risk factors, with the exception of baseline socioeconomic/lifestyle risk factors, in which a linear association emerged. Adjustment for waist circumference eliminated risk in the obese. Finally, weight gain during follow-up was protective. Conclusion: The relationship of adiposity with mortality in T1D now seems to resemble that of the general population, albeit with a marked increased risk in those who are underweight.
Mortality in type 1 diabetes (T1D) is greatly accelerated, occurring several decades earlier than in the general population. [1] [2] [3] [4] [5] Although adiposity is associated with an increased risk of many chronic diseases in the general population, [6] [7] [8] [9] there is some evidence that this relationship may not be so straightforward, particularly for mortality, wherein U-and J-shaped relationships are often observed. [10] [11] [12] [13] [14] Furthermore, within diseased populations, increased adiposity is often associated with longer survival. [15] [16] [17] Within T1D, coronary artery disease (CAD) is the leading cause of death overall, although renal disease, especially at shorter-and medium-term durations of diabetes, is also a major contributor. 1, 18, 19 Chronic complications such as these are a part of the natural history of T1D and thus may confound the relationship of adiposity with mortality. Furthermore, in T1D, the association of overweight and obesity with mortality may be further complicated, as intensive insulin therapy (IIT) is associated with both weight gain and a reduction in complications.
Few studies have fully investigated adiposity as a risk factor for mortality in T1D. In the studies in which it was considered, adiposity has not been shown to be a risk factor for mortality, [19] [20] [21] with the exception of that by Roy et al., 22 in which adiposity was associated with longer survival. However, with the marked increase in overweight and obesity, leading to a much wider range in adiposity, this situation may be changing. This paper investigates the association of adiposity with mortality, above and beyond the known risk factors for mortality in T1D. To serve the needs of the practicing clinician and to account for confounding and address reverse causation, adiposity is investigated as both a baseline predictor and as a function of body mass index (BMI) change over an 18-20- year time period.
Methods
The Pittsburgh Epidemiology of Diabetes Complications Study (EDC) is a prospective study based on a well-defined cohort of individuals with childhood onset (o17 years old) T1 diabetes mellitus. Eligible individuals (n=658: 325 women and 333 men; 98% Caucasian) were diagnosed between 1st January 1950 and 30th May 1980 and first examined for the EDC between 1986-1988; 654 of these individuals provided BMI and some follow-up data. Mortality follow-up was censored on January 1, 2008. At biennial cycles of examinations, information was collected with regard to demographic characteristics, medical history and health-care behaviors, as previously described. 23, 24 At each cycle, both a standardized medical history and a clinical examination were carried out by a trained internist to document complications of diabetes.
Participants were weighed in light clothing and without shoes on a balance beam scale. Height was measured using a stadiometer. BMI was calculated as the weight in kilograms divided by the square of the height in meters. For the first 10 years of follow-up, height and weight were measured. Beginning in 1998, exams were limited to certain subgroups, so measured height and weight data were not fully available until 2004-2007, when an 18-year follow-up exam was again made available to all participants. Selfreported data from the medical history questionnaire were used when measured data were not available, representing 83 and 33% of the data from the 12th and 16th year followup periods, respectively. The validity of the reported height and weight has been reported. 25 Underweight was defined as a BMI o 20 kg/m 2 ; normal weight as 20 kg/ m 2 pBMIo25 kg/m 2 ; overweight as 25 kg/m 2 pBMIo30 kg/ m 2 and obesity as BMIX30 kg/m 2 . Weight change was defined as BMI at the 10-year follow-up exam minus baseline BMI.
Fasting blood samples were assayed for lipids, lipoproteins, glycosylated hemoglobin (HbA1), creatinine and hematocrit. High-density lipoprotein (HDL) cholesterol was determined by a heparin and manganese procedure, a modification 26 of the Lipid Research Clinics method. 27 Cholesterol was measured enzymatically. 28 Stable glycosylated hemoglobin A1 (HbA1) was originally measured in saline-incubated samples by microcolumn cation-exchange chromatography (Isolab, Akron, Ohio, USA). On 26 th October 1987, the method was changed to high-performance liquid chromatography (HPLC) (Diamat, Bio-Rad Laboratories, Hercules, CA, USA). The two methods were highly correlated (r ¼ 0.95). Beginning in 1998, HbA1c was measured using a DCA2000 analyzer (Bayer Diagnostics, Tarrytown, NY, USA). Original HbA1 (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) and A1c (1998-2004) were converted into Diabetes Control and Complications Trial (DCCT)aligned HbA1c values, using regression formulas derived from duplicate analyses (DCCT HbA1c ¼ (0.83 * EDC HbA1) þ 0.14; DCCT HbA1c ¼ (EDC HbA1cÀ1.13)/0.81). Blood pressure was measured by a random-zero sphygmomanometer according to a standardized protocol, 29 after a 5-min rest period. Blood pressure levels were analyzed, using the mean of the second and third readings. Insulin dose per kg of body weight was defined as the total daily units of insulin divided by the body weight in kilograms.
IIT was defined as administering three or more insulin injections per day or by using an insulin pump. Physical activity was determined by the number of flights climbed per day and city blocks or equivalent walked per day; and mets calculated from sports/exercise Â minutes of participation Â number of times per week, and is expressed in kilocalories. Complications were assessed as described earlier, 23, 24 and overt nephropathy (ON) was defined as albumin excretion rate 4200 mg min À1 in two of three timed urine samples 30 or a history of renal dialysis or transplant. All procedures were approved by the Institutional Review Board of the University of Pittsburgh.
Statistical analyses
The Student's t-test and w 2 tests were used to examine the univariate associations of BMI category with mortality risk factors. Cox proportional hazards modeling was used to determine the independent predictive ability of BMI category on mortality, with normal weight being used as the reference. Risk factors were grouped into three categories (complications, biological risk factors and socioeconomic/ lifestyle risk factors), and models fitted separately for each group as predictors of mortality. The number of participants included in different statistical models varied because of item nonresponse. Preliminary analyses showed that the relationship of BMI category with mortality was essentially similar in each sex; therefore sex-specific analyses were not carried out. Children younger than 18 years of age (n ¼ 66) were excluded from baseline analyses. Cox models with baseline risk factors were used to determine the association of baseline BMI category on mortality. Cox models with updated mean covariates were also used to determine the association of average BMI status during follow-up with mortality. The updated mean was determined by taking the average value of a risk factor during follow-up. For dichotomous variables, the updated variable was entered as the number of years with the given risk factor. The forward selection procedure was used to identify the most predictive risk factors; BMI category was forced into all models. Cox models with time-varying covariates were used to determine the association of the most recent BMI status with mortality. To account for the colinearity between BMI and waist circumference, the residuals of BMI regressed on waist circumference were used in models incorporating waist circumference. Finally, Cox modeling was also used to determine the association of the residuals of weight change with mortality in adults who were at least 18 years old at baseline. Variables are expressed as per standard deviation change in the continuous variable. All tests were two-tailed and a P-value o0.05 was considered significant. All analyses were conducted using Statistical Analysis Software (SAS) version 9.1 (Cary, NC, USA).
Results
BMI data were available on 655 participants, and 99.8% (654) provided some follow-up data. Participants (mean age and diabetes duration: 28 and 19 years, respectively) were followed for a median of 18.2 years (range: 0.2-20.6 years). There were 146 deaths (22%).
Baseline characteristics of the participants (aged 18 years and older) by BMI category are described in Table 1 . At baseline, compared with normal-weight participants, obese participants had a higher non-high density lipoprotein (non-HDL) cholesterol level. Overweight participants also had, compared with those of normal weight, a lower HbA1c, were on more insulin injections per day, had a higher diastolic blood pressure, a lower HDL cholesterol level, a lower prevalence of symptomatic autonomic neuropathy, and were less likely to be current smokers.
During follow-up, the prevalence of IIT (IIT-3 þ insulin shots daily and/or pump) increased from 7 to 82%. 25 The prevalence of being overweight increased from 28.6 to 42.0%, whereas the prevalence of obesity increased sevenfold (from 3.4 to 22.7%) over an average of 18 years of followup. 30 Figure 1 shows the unadjusted association of mortality with baseline BMI category (panel a), updated mean BMI status during follow-up (panel b), and the most recent BMI status before event or censoring (panel c). Baseline BMI showed a slight U-shape relationship with mortality (P for quadratic term ¼ 0.002), such that there was a higher risk in the underweight relative to the normal weight and a markedly higher level of risk in the obese. However, average BMI during follow-up (updated means model) showed a reverse J-shaped relationship with mortality, such that those with an average BMI in the obese category were at a slightly increased risk of mortality relative to those in the normal BMI and mortality in T1D B Conway et al weight category, but the highest risk was in those with an average BMI less than 20 kg/m 2 (P for quadratic term o0.0001). The BMI nadir for mortality risk fell in the overweight category. In the time-varying model, reflecting the most recent BMI status before event or censoring, the risk in the underweight and obese seemed to be even stronger, compared with that in the baseline and updated means models, with the risk in the underweight being thrice and that in the obese being twice that of the normal weight (P for quadratic term o0.0001).
The results of modeling baseline risk markers according to type, namely, complications, biological risk factors, or socioeconomic/lifestyle risk factors are shown in Table 2 . As sample size with full data available varies for these three riskmarker categories, the base models show the relationship of BMI category with mortality, specific for that population, adjusted only for age and sex. The increased risk in the obese was attenuated after adjustment for chronic complications of diabetes, and eliminated after adjustment for biological and socioeconomic risk factors. The multivariable baseline models thus showed weak U-and J-shaped relationships with mortality. Table 3 shows the relationship of updated mean BMI category with mortality. In contrast to the baseline model, average BMI status during follow-up showed a strong U-shaped relationship with mortality even after adjustment for the proportion of follow-up time spent with complications. Adjusting for these complications did not account for the increased risk in the underweight or obese. Similarly, compared with the base model, adjusting for updated mean biological risk factors had very little effect on the BMI relationship with mortality. However, adjusting for socioeconomic/lifestyle risk factors, including IIT, which emerged as a protective factor, eliminated the risk in the underweight, whereas no substantial change in risk in the obese was noted. Table 4 shows the relationship of the most recent BMI status with mortality. Adjusting for time-varying complication status seems to attenuate the risk in the underweight compared with that in the base model, whereas adjusting for time-varying biological or socioeconomic/lifestyle risk factors does not seem to have a substantial effect on the relationship of BMI category with mortality. When compared with the baseline and updated means models, whether adjusting for complications, biological risk factors or socioeconomic/lifestyle risk factors, base and adjusted time-varying models show a stronger (larger effect size) adverse relationship with being underweight.
The Spearman correlation between BMI category and waist circumference at baseline was 0.68 (Po0.0001). When ageand sex-adjusted waist circumference was modeled instead of BMI, baseline waist circumference was an independent predictor of mortality (hazard ratio (HR) ¼ 1.33, 1.11-1.60, P ¼ 0.003); however, updated mean waist circumference showed a U-shaped relationship with mortality (P ¼ 0.0002). Similar results as those in the updated mean were obtained for the time-varying analysis (P ¼ 0.009 for age-and sex-adjusted quadratic term). To determine if this relationship of waist circumference with mortality accounted for the relationship of excess BMI with mortality, the residuals of BMI regressed on waist circumference were BMI and mortality in T1D B Conway et al added to the model with age-and sex-adjusted waist circumference. Baseline waist circumference remained an independent positive predictor of mortality (HR ¼ 1.43, 1.19-1.72, P ¼ 0.002), whereas baseline BMI residuals showed an inverse relationship with mortality (HR ¼ 0.84, 0.76-0.93, P ¼ 0.0008). The relationship of the updated mean waist circumference remained quadratic (P ¼ 0.0004) and, as in the baseline model, the residuals of updated mean BMI remained inversely associated with mortality (HR ¼ 0.88, 0.80-0.97, P ¼ 0.01). Similar results to those seen in the updated means models were observed in the time-varying model, that is, waist circumference showed a quadratic relationship with mortality (P ¼ 0.004), whereas BMI was inversely associated with mortality (HR ¼ 0.90, 0.83-0.98, P ¼ 0.01). Figure 2 shows the association of change in BMI in adults during the first 10 years of follow-up with mortality during the subsequent 10 years. BMI change ranged from À6.5 to 11.0 kg/m 2 . There was a significant trend for a positive change in BMI to be associated with lower mortality, such that for each tertile of change, risk was reduced by approximately one-third (P for trend ¼ 0.01). In multivariable analysis in adults 18 years and older, after controlling for baseline BMI, age, and albumin excretion rate, and allowing for IIT and other univariate significant risk factors, each 1-unit positive change in the residuals of BMI change during the first 10 years of follow-up was associated with a 12% decreased risk of mortality during follow-up years 11-20 (HR ¼ 0.88, 0.80-0.97) ( Table 5 ). When this analysis was repeated, stratified by a BMI less than 25 kg/m 2 , similar results were obtained for the normal/underweight (HR ¼ 0.79, 0.69-0.92, n ¼ 225) and for the overweight/obese (HR ¼ 0.88, 0.75-1.04, n ¼ 101), although the effect was stronger for those with a BMI less than 25 kg/m 2 (P-value for interaction ¼ 0.0003) (data not depicted).
Discussion
In this report, we have documented the association of both baseline BMI and BMI measured repeatedly during follow-up with mortality in T1D. To our knowledge, this is the first study to document the long-term association of adiposity with mortality in T1D, in which adiposity was the predictor of interest. We have shown that baseline BMI showed a slight U-shaped relationship with 20-year mortality. We have also shown during follow-up that the role of underweight as a predictor increases, and conversely, we have also shown that weight gain in adults with T1D is protective against mortality. Finally, we have shown that the role of overweight and obesity in increasing mortality seems to be largely mediated by waist circumference. The relationship of BMI with mortality in this population was not linear, neither at baseline nor throughout follow-up. Although Roy et al., 22 found BMI to be inversely associated with mortality (HR ¼ 0.94, 0.91-0.97) in a large African-American population with T1D, in general, in T1D, the relationship of BMI with mortality has been reported to be nonsignificant, although apart from the present study, no study has specifically looked at mortality in this population, with BMI as the explanatory variable of interest. The association of BMI with mortality in the general population is usually found to exhibit a U-or J-shaped curve, although some argue that this may be because of the failure to exclude pre-existing disease, smoking or recent weight loss. [31] [32] [33] Against this, others have shown that even after excluding pre-existing disease, smoking or recent weight loss, this nonlinear relationship persists. 13, 34, 35 Excluding pre-existing disease in T1D may be debatable, as T1D itself is a preexisting disease. Furthermore, 55% of our adult population at baseline, with a mean age of 29, had at least one of the long-term diabetes complications at study entry, and 23% of our adult population at baseline were smokers; therefore, exclusion of smokers and those with preexisting disease would not be representative of the T1D population. However, we have attempted to account for weight loss, smoking and longterm complications by looking at them biennially in updated means and time-dependent survival analyses. In our population, after examining the association of BMI on mortality with up to 20 years of follow-up, BMI failed to show a linear relationship with mortality, demonstrating a relationship similar to that observed in the general population, with the exception of a much increased risk in those whose average or most recent BMI was in the underweight category.
Untreated T1D is a wasting disease, characterized by a severe deficiency or an absolute absence of the anabolic hormone, insulin, essential to ensuring the intake of energy into cells and the prevention of muscle and fat catabolism. Without this hormone, the natural history of the disease would be a progressive wasting to death. Upon correction of wasting by exogenous insulin, an alternate natural history commences. This alternate natural history includes progressive kidney disease, with its sequelae of hypertension leading to further progression of kidney disease, leading to an atherogenic lipid profile, anorexia, and wasting in its final stages. This alternate natural history also includes very early cardiovascular disease, autonomic neuropathy with its dysphagia, anorexia and early satiety, other neuropathies causing muscle wasting or limited mobility because of pain, bone deformities or amputations. It includes blindness, with its limitation on mobility, and peripheral vascular disease, the latter also causing limited mobility because of pain or amputations. Finally, this natural history ends with very early mortality, with its obvious limit on the time in which weight gain can occur and its implications for adiposity as in populations with limited longevity, increased adiposity tends to be protective. Any effects of or on adiposity within T1D must take place within this environment, and to the extent that these effects mirror the general population, whether good or bad, these represent a major accomplishment in T1D.
A major biological risk factor for mortality in our population was HbA1c. HbA1c has been shown previously to be a risk factor for mortality in T1D, 1, 36 and Shankar et al. 36 noted that the mortality risk associated with HbA1c was greater at a higher BMI, although this was not noticed by Stadler et al. 1 In this population, both HbA1c and IIT were positive predictors of weight gain; 30, 37 however, in the prediction of mortality, although HbA1c was directly predictive, the average amount of time spent on IIT during follow-up was protective. We have thus shown a complex interaction between catabolic and anabolic factors over the approximately two decades of follow-up. Intensification of insulin therapy increased dramatically, whereas HbA1c, a marker of glycemic control, showed a substantial reduction, both factors directly associated with weight gain via a reduction in catabolic tissue breakdown and glycosuria, and an increase in adipose tissue storage. They are also indirectly associated with weight gain via a reduction in complications associated with wasting, that is, nephropathy and autonomic neuropathy. 38 Nevertheless, although the progression of the natural history of the disease has slowed, it has not halted, and for coronary artery disease, little improvement has been made 3 , and after 18 years of follow-up, the EDC population is considerably older with considerably more complications, and thus the wasting process may still be operant. The effect of change in weight over time is another dimension of the complex association of adiposity with mortality in T1D. In adults aged 18 years and older, we observed a protective effect of weight gain, as assessed by BMI and mortality, such that with each increasing tertile of change, mortality was reduced by approximately 33%. Although it is not unexpected for weight loss to predict mortality in a population with preexisting disease, that is, T1D itself, we found that weight gain had beneficial survival effects beyond that of even the relatively weight stable, an observation that should be underscored, as the average baseline BMI in this population was 23.8 kg/m 2 , a value well within the normal weight range. Weight change modeled as a continuous variable was inversely associated with mortality, even after adjustment for other factors associated with mortality. Although weight gain in adulthood has been reported to be a positive predictor of mortality, 35 and weight loss to be beneficial if volition is taken into account, 39, 40 in the main, general population studies have shown an inverse or U-shaped relationship between weight change and mortality, [41] [42] [43] even when preexisting illness and smoking have been taken into account. 44, 45 In our population with T1D, with a mean age of 29 years at baseline, weight gain also appeared to be protective against mortality in middle age.
A major observation of this study was that waist circumference accounted for the U-shaped relationship of BMI with mortality. Some have hypothesized that, contrary to being due to a failure to adequately control for smoking, subclinical or occult disease, the nonlinear relationship observed between BMI and mortality may be a consequence of BMI being a composite of both fat and fat-free mass, [46] [47] [48] and not simply a surrogate for overall adiposity. Bigaard et al. 48 showed that the U-shaped relationship between BMI and mortality was due to the J-shaped relationship of fat mass and the reverse J-shaped relationship of fat-free mass with mortality. Several studies have shown that adjustment for waist circumference, a surrogate for abdominal adiposity, [49] [50] [51] [52] eliminates or attenuates BMI's nonlinear relationship with mortality. 53, 54 In our T1D population as well, adjustment for waist circumference also eliminated the U-shaped relationship between BMI and mortality and the relationship became inversely linear. Beyond suggesting that the effect of obesity on mortality is largely mediated through central adiposity, this is suggestive of a protective effect for both peripheral body fat and for lean body mass. Consistent findings have also been reported in the literature. 46, 55, 56 Strengths and limitations Major strengths of our study include the prospective nature of the design, measured height and weight, repeated assessment of height and weight as well other riskfactors over time, and a long follow-up period. As BMI was assessed every 2 years, we were able to assess the effects of weight change on mortality, showing an increased risk in those who lost weight and a decreased risk in those who gained the most weight, a weight gain well beyond a normalization of weight.
A major strength of this paper could also be one of its limitations. As this study tracked mortality over 20 years, changes in both diabetes treatment and risk factor management associated with obesity may have affected mortality results. However, we have attempted to account for this, as well as for weight change, in the time-varying covariate models. Results from these models did not show a major change in the association of obesity with mortality, but they did show a much stronger relationship with being underweight and a reversal of the relationship of being overweight with mortality, even after long-term diabetes complications and IIT were taken into account. This would seem to suggest that with improved diabetes treatment and risk-factor management, a modest increased adiposity is actually beneficial, as also suggested by our analysis of weight change.
Conclusion
With the rise in overweight and obesity in T1D, and the rise in IIT, the traditional view of T1D as a starvation state is clearly outdated. Nevertheless, an interaction between catabolic and anabolic imbalances is evidenced by the increased risk in the obese and the greatly increased risk in the underweight. Although an understanding of the risk associated with obesity is of interest, in terms of a disease traditionally characterized by relative thinness and enhanced catabolism, of greater concern maybe the excess mortality risk due to leanness. Given the wide BMI range associated with minimal mortality (20-29 kg/m 2 ), weight gain is not necessarily a bad occurrence in T1D. Although frank obesity should be avoided, risk-factor management may be better focused on glycemia, blood pressure and lipids, and on other complication-specific risk factors, than on overweight per se.
